Human Raf1 kinase inhibitory protein (hRKIP) is an important modulator of the Ras/Raf1/MEK/ERK signaling pathway. Here, we demonstrated that anti-leprosy drug Clofazimine can bind to hRKIP with a significantly stronger affinity than the endogenous substrate phosphatidylethanolamine (PE) by using Biolayer interference technology. Moreover, we identified that residues P74, S75, K80, P111, P112, V177, and P178 play crucial roles in the binding of hRKIP to Clofazimine by using a combination of Nuclear Magnetic Resonance spectroscopy and molecular docking approach. These residues are located at the conserved ligand-binding pocket of hRKIP. Furthermore, we found that 3.2 μM Clofazimine could significantly increase the ERK phosphorylation level by about 37%. Our results indicate that Clofazimine can enhance Ras/Raf1/MEK/ERK signaling transduction pathway via binding to hRKIP. This work provides valuable hints for exploiting Clofazimine as a potential lead compound to efficiently treat the diseases related to RKIP or the Ras/Raf/MEK/ERK pathway.
Introduction
Raf1 kinase inhibitory protein (RKIP) is a member of phosphatidylethanolamine (PE) binding protein family, which possesses a conserved ligand-binding pocket and can negatively regulate mammalian Ras/ Raf/MEK/ERK signaling cascade [1, 2] . As is well-known, the Ras/ Raf/MEK/ERK signaling transduction pathway plays pivotal roles in gene regulation and cellular function [3] . It was previously reported that this cascade is highly related to tumor transformation, growth and malignant evolution [4] .
RKIP down-regulates the Ras/Raf/MEK/ERK pathway by directly binding with the Raf1 kinase. The abnormal expression of RKIP is associated with many cancers, such as prostate cancer, breast cancer, and melanoma [5] [6] [7] . Therefore, it is intelligible to explore inhibitors and agonists against RKIP to regulate the Ras/Raf/MEK/ERK signaling pathway. Here, we reported a novel binding ligand of human RKIP (hRKIP), Clofazimine, which has a marked anti-inflammatory effect in clinical practice and is currently used as an anti-leprosy drug. We demonstrated the interaction of Clofazimine with hRKIP by the Biolayer interference (BLI) technique, and determined the binding sites of Clofazimine on hRKIP by Nuclear Magnetic Resonance (NMR) experiments. Furthermore, we explored the regulatory role of Clofazimine in the hRKIP-mediated Ras/Raf/MEK/ERK signaling pathway.
Materials and Methods

BLI assays
Intermolecular interactions between hRKIP and ligands were detected by using BLI technology on the ForteBio Octet Red system (ForteBio, Inc, Menlo Park, USA). Both PE (Product No. P0503) and Clofazimine (Product No. C8895) were purchased from SigmaAldrich (St Louis, USA). Recombinant His-tagged hRKIP proteins were prepared according to the procedure we described previously [8] . The His-tagged hRKIP proteins were immobilized onto Ni-NTA reactive biosensors, and the captured biosensors were individually dipped into wells containing various concentrations of either PE (1.25, 2.5, 5, 10, and 20 mM) or Clofazimine (62.5, 125, 250, 500, 1000 μM). The sensors loading hRKIP without ligands were used as controls to correct baseline drifts. The reference responses were conducted in the wells containing various concentrations of ligand without the loading protein. Association and dissociation responses were processed by using the Octet Software Data Analysis (Version 7.0; ForteBio). The Langmuir's 1:1 binding model was applied to fit the interferometry data.
NMR analysis
15 N-labeled hRKIP proteins were prepared from 1 l of M9 minimal medium ( N-labeled hRKIP solution to maximize the solubility, and stirred at room temperature overnight. Then, the insoluble content was removed by centrifugation prior to NMR experiments. For NMR titration experiments of PE, the stock solution (180 mM) of PE was stepwisely added into the hRKIP solution till the final concentration reached 18 mM. NMR spectra were processed using the NMRPipe program [9] and analyzed using the CCPNmr software [10] . 
Identification of ligand-binding sites on the protein
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Molecular docking
The Genetic Optimization for Ligand Docking (GOLD) program was used to build the structural model of the hRKIP-Clofazimine complex [11] . The three-dimensional (3D) structure of hRKIP in solution was obtained from the Protein Data Bank (PDB ID: 2L7W). The binding sites of Clofazimine on hRKIP were defined based on the coordinate centers of the amino acids which underwent significant CSPs in the 1 H-15 N HSQC spectra. For the molecular modeling, 20 genetic algorithm runs (docking attempts) were conducted with the possibility of early termination at each round. The search efficiency of the genetic algorithm was set at the standard 100% setting. The qualities of the built structural models were evaluated by using the ChemPLP scoring function [12] . The lowest energy conformation model with the highest score was used for further analysis. Structural representations were prepared using the PyMOL software.
Analysis of ERK phosphorylation level
First, the cell toxicity of Clofazimine was detected on human embryonic kidney 293T cells (HEK 293T) with the MTT method by incubating the cells with various concentrations of Clofazimine (from 0.05 μM to 12.8 μM) as previously described [13] . Then, the regulatory role of Clofazimine in hRKIP-mediated Ras/Raf/MEK/ERK signaling pathway was investigated. HEK 293T cells (CCTCC, Shanghai, China) were cultured in Dulbecco's modified Eagle's Medium (DMEM) supplemented with 10% (v/v) fetal bovine serum (Gibco, Grand Island, USA) and cultured at 37°C with 5% (v/v) CO 2 . At 80% confluency, 3.2 μM Clofazimine was added and cells were further incubated for 24 h. Thereafter, cells were stimulated with 400 ng/ml tumor promoter (TPA; Beyotime, Shanghai, China) for 15 min. The cells were collected and re-suspended in 150 μl of Radio Immunoprecipitation Assay lysis buffer containing phenylmethylsulfonyl fluoride and phosphatase inhibitors (Sigma-Aldrich, St Louis, USA). Then, the cells were lysed at room temperature for 15 min, and the supernatant was collected by centrifugation and resolved by 15% SDS-PAGE. ERK phosphorylation level assays were performed following the procedure we previously described [14] using antiphospho-ERK antibody as the first antibody (Cell Signaling Technology, Danvers, USA). β-Actin was used as a loading standard. The digital analysis of immunoreactivity was conducted with the ImageJ software.
Statistical analysis
Experimental data of cells are presented as the mean ± standard deviation (SD). Statistical significance was determined using Student's t-test. P < 0.05 was considered statistically significant.
Results and Discussion
Clofazimine has a stronger affinity for hRKIP than PE
We quantitatively compared the affinity of Clofazimine in binding to hRKIP with that of the endogenous substrate PE. As shown in Fig. 1 , both Clofazimine and PE exhibited concentration-dependent sensorgrams within the tested range. Clofazimine showed a stronger affinity in binding to hRKIP than PE. The BLI response level at 1 mM Clofazimine was around 0.9 nm, while that at 20 mM PE was only 0.25 nm. The kinetic analysis of hRKIP interacting with the ligand was performed based on a single-site binding model. Both association rate (k a ) and dissociation rate (k d ) of Clofazimine interacting with hRKIP were higher than those of PE. In detail, k a was 1.17 × 10 (Fig. 2) .
Binding sites of Clofazimine on hRKIP
The overlaid 15 N-labeled hRKIP HSQC spectra showed that the backbone N-H peaks of 13 residues were significantly shifted after the addition of Clofazimine (Fig. 3A) . These residues showed larger CSP data than the sum of the mean value and the standard deviation statistically obtained from the CSP data of all the non-proline residues in hRKIP (Fig. 3B) . The 13 shifted residues did not show visible broadened peaks or disappeared peaks, suggesting that the K D value of hRKIP interacting with Clofazimine was probably larger than 10 −5 M [15] . This observation supports the BLI measurement described above (K D = 106 μM). RKIP has a conserved ligand-binding pocket which can bind a wide range of ligands such as Raf1 kinase, and PE [2, 16] . The ligandbinding pocket comprises residues located at the C-terminal helix and the loops in the highly conserved region from residues 63 to 126 [17] (Fig. 3C) . Based on resonance assignments of hRKIP (BMRB accession code 16992), the 13 significantly shifted residues were identified to be V3, D72, S75, H85, S109, R141, S142, G143, D144, V177, E182, Q183, and G186. Two terminal residues V3 and G186 were excluded from the identification of the binding sites. More significantly, residues D72, S75, H85, S109, V177, E182, and Q183 are located at the conserved ligand-binding pocket of hRKIP (Fig. 3D) , suggesting that Clofazimine primarily binds to the ligand-binding pocket of hRKIP.
NMR titration experiments were also performed to map the binding sites of PE on hRKIP. The perturbed residues with significantly shifted peaks in 2D 1 H- 15 N HSQC spectra were mapped to the 3D structure of hRKIP (Fig. 3E) . The result suggests that PE also primarily binds to the ligand-binding pocket of hRKIP. Notably, PE and Clofazimine have similar but different binding sites. The binding sites of PE were primarily located at the bottom of the pocket, such as D70, E83, W84, H85, and F87. These binding sites are similar to those determined from the previous study on the interaction of bovine RKIP with PE, in which hydrogen bonds make significant contributions [18] . Differently, the binding sites of Clofazimine were mostly located at the entrance of the pocket in hRKIP. Therefore, the binding mode of Clofazimine for hRKIP is different from that of PE.
Structural model of Clofazimine binding to hRKIP
The molecular docking of hRKIP with Clofazimine was shown in the Supplementary Fig. S1 . The built structural model of the hRKIPClofazimine complex illustrates that Clofazimine is mainly incorporated into a hydrophobic pocket of hRKIP by hydrophobic interactions (Fig. 4A) . Dihydrophenazin of Clofazimine contacts residues S109, P111, P112, V177, and P178 contained in the hydrophobic pocket of hRKIP. P112 forms a Pi-Alkyl bond with the isopropylimino group of Clofazimine. Moreover, P111 forms a hydrophobic interaction with the isopropylimino-substituted six-membered ring at the dihydrophenazin core of Clofazimine, which in turn immobilizes the dihydrophenazin. Furthermore, V177 and P178 form hydrophobic interactions with the 4-chlorophenyl at Position 5 of phenazin via Pi-Alkyl bonds. P74 and S75 are located at the other end of the ligand-binding pocket, and S75 binds with Clofazimine through van der Waals interaction. Additionally, electrostatic interaction between the residue K80 and the chlorophenyl at the 1-position of the dihydropyridazine immobilizes the other end of Clofazimine to contact hRKIP. In general, Clofazimine binds to hRKIP at its conserved ligand-binding pocket primarily through hydrophobic interactions, and electrostatic interactions somewhat stabilize the hRKIP-Clofazimine complex (Fig. 4B) . 
Regulatory role of Clofazimine in hRKIP-mediated Ras/ Raf/MEK/ERK pathway
Our previous study showed that the N-terminus of human Raf1 (hRaf1 1-147aa ) also primarily binds to the ligand-binding pocket of hRKIP with a dissociation constant of 154 μM, and D72, P74, S109, and P112 are also the key residues for hRKIP binding with hRaf1 1-147aa [19] . We speculated that Clofazimine might interfere with the interaction between hRKIP and Raf1, and affect the Ras/ Raf/MEK/ERK signal pathway. To confirm this speculation, we exploited the effect of Clofazimine on hRKIP-mediated Ras/Raf/ MEK/ERK pathway by detecting the phosphorylation level of ERK. The cytotoxicity test showed that HEK 293T cells grew normally in the presence of 3.2 μM Clofazimine (Fig. 5) . Therefore, we incubated HEK 293T cells with 3.2 μM Clofazimine for 24 h, and stimulated them with 400 ng/ml TPA for 15 min. Then, the ERK phosphorylation level was analyzed by western blot analysis (Fig. 6A) . The digital analysis of the immunoreactivities indicated that 3.2 μM Clofazimine increased the intracellular ERK phosphorylation level by about 37% (Fig. 6B) . It has been demonstrated that the Ras/Raf/MEK/ERK pathway plays crucial roles in a number of basic cellular processes and its disregulation is related to many cancers [3] . As RKIP is a regulator of the Ras/Raf/MEK/ERK signal pathway, intensive efforts have been made to develop inhibitors and aganoists of RKIP to regulate this pathway. A number of RKIP ligands have been reported, however their effects on the Ras/Raf/MEK/ERK pathway remains less defined. To our knowledge, only locostatin was identified to bind to the ligandbinding pocket of RKIP, and could enhance the Ras/Raf/MEK/ERK signaling pathway [20] . Shemon and others screened out three compounds capable of binding to hRKIP, however, these compounds did not show any regulatory effect on the RKIP-mediated MAPK signal pathway [17] . DHPE (1,2-dihexanoyl-sn-glycero-3-phosphoethanolamine) was also found to be capable of binding to hRKIP, however, its regulatory role in ERK phsoshporylation has not been defined yet [2] . In our previous study, we found that 25 μM Pranlukast could also bind to hRKIP and increase the ERK phosphorylation level by around 17% in HEK 293T cells [14] . Herein, we demonstrated that Clofazimine could bind to hRKIP, and further determined its binding sites on hRKIP. In addition, we also explored its effect on the Ras/ Raf/MEK/ERK pathway, and showed that 3.2 μM Clofazimine increased the ERK phosphorylation level by about 37% in HEK 293T cells, which was significantly higher than Pranlukast [14] .
Clofazimine was originally developed as an anti-mycobacterial drug and then used as an anti-leprosy drug. Clofazimine functions through binding to the guanine bases of bacterial DNA, and inhibiting bacterial proliferation [21] . In the present study, we reported for the first time that Clofazimine can bind to hRKIP and significantly enhance the ERK phosphorylation level, which might expand the potential applications of Clofazimine in clinical practice. However, it has also been demonstrated that Clofazimine can cause pink to brownish skin pigmentation in patients and these discolorations may take months or even years to disappear, as the biological halflife of Clofazimine is about 70 days in vivo [22] . Although 3.2 μM Clofazimine is significantly less than its recommended dose in clinical practice (100-300 mg) used for treating leprosy patients, more efforts are needed to eliminate the side-effects of Clofazimine.
In summary, we identified that Clofazimine is a novel ligand of hRKIP. It binds to the conserved ligand-binding pocket of hRKIP, and has a stronger affinity for binding to hRKIP relative to the endogenous ligand PE. Furthermore, we found that 3.2 μM Clofazimine could enhance the intracellular ERK phosphorylation level by about 37%. Our results indicate that Clofazimine can act as a lead compound for prospectively improving and developing potential drugs to efficiently treat the diseases related to hRKIP or the Ras/Raf/MEK/ERK pathway.
Supplementary Data
Supplementary data is available at Acta Biochimica et Biophysica Sinica online.
Funding
This work was supported by the grants from the Natural Science Foundation of China (Nos. 31470034 and 31670741) and the Densitometric analysis of p-ERK/β-actin levels using the ImageJ software. The p-ERK/β-actin level is set to 100% for the control cells. **P < 0.01, compared with the control cells. Data are shown as the mean ± SD (n = 3).
